Comparative Pharmacology
Head-to-head clinical analysis: BINIMETINIB versus MEKINIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BINIMETINIB versus MEKINIST.
BINIMETINIB vs MEKINIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binimetinib is a reversible, non-ATP-competitive allosteric inhibitor of MEK1 and MEK2, blocking downstream ERK phosphorylation and signaling in the RAS-RAF-MEK-ERK pathway.
Reversible, selective inhibitor of MEK1 and MEK2, which are downstream kinases in the RAS/RAF/MEK/ERK signaling pathway. Inhibition prevents phosphorylation and activation of ERK, thereby reducing cell proliferation in BRAF V600 mutant tumors.
45 mg orally twice daily.
2 mg orally once daily, at least 1 hour before or 2 hours after a meal.
None Documented
None Documented
Terminal elimination half-life is approximately 3.5–4 hours at steady state; no significant accumulation observed with twice-daily dosing.
Terminal half-life of 3.9 days (93.6 hours) in patients; supports once-daily dosing and steady-state achieved in ~19 days
Primarily hepatic metabolism with biliary-fecal elimination; unchanged drug in urine is negligible (<1%). In mass balance studies, ~70-80% of the dose is recovered in feces (mainly as metabolites) and <20% in urine (as metabolites).
Fecal (80% as unchanged drug and metabolites), renal (<1% unchanged)
Category C
Category C
MEK Inhibitor
MEK Inhibitor